What Adcirca Treats: Main Uses and Benefits

Adcirca (tadalafil) is generally applied in the long-term management of Pulmonary Arterial Hypertension (PAH), specifically designated as WHO Group 1 disease. It is generally applied in the management of conditions where functional stability becomes affected, particularly in patients classified as WHO Functional Class II or III. The medicine is commonly used to help with improving exercise capacity in adults.

Therapeutic Scope and Functional Support

The primary condition it addresses is PAH, and it is commonly used across conditions characterized by periods of heightened symptoms, including both idiopathic PAH and PAH associated with other ailments like certain connective tissue diseases. Adcirca is used for managing symptom clusters that interfere with daily functioning, such as severe shortness of breath (dyspnea), fatigue, and weakness experienced during routine physical activity. It supports patients during episodes of heightened discomfort by contributing to easing the overall symptom burden linked to systemic imbalance. This supports an enhanced functional status and contributes to improved day-to-day comfort.

---

Quick Fact: Relief for Exertional Dyspnea

Adcirca is commonly used to address shortness of breath that occurs with activity, providing supportive relief when symptoms interfere with routine activities. It plays a role in managing symptoms that create noticeable physiological strain.

Official Eligibility and Non-Eligibility for Adcirca

Adcirca (tadalafil) is indicated for use in adults diagnosed with Pulmonary Arterial Hypertension (PAH), specifically those classified as WHO Functional Class II or III. Use in pediatric patients under 18 years of age is not generally recommended by the FDA, as safety and efficacy have not been established in this group.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by patients taking any form of organic nitrates (regularly or intermittently) or Guanylate Cyclase (sGC) stimulators (e.g., riociguat), due to the risk of severe hypotension. Contraindication also applies to patients with a known serious hypersensitivity to tadalafil and those with a history of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). Specific severe cardiovascular events, such as myocardial infarction within the last 90 days or stroke within the last six months, also define non-eligibility.

Populations Requiring Restriction

Use is not recommended in patients with severe renal impairment or severe hepatic cirrhosis (Child-Pugh Class C) due to limited clinical experience and altered drug exposure. For pregnancy and lactation, use is not recommended; it should only be used if the potential benefit outweighs the potential risk, as stated in regulatory labeling.

Interactions with Other Medicines and Products

Adcirca (tadalafil) has documented interaction patterns primarily involving two mechanisms: pharmacodynamic potentiation and metabolic clearance alteration.

Co-administration with organic nitrates and Guanylate Cyclase (GC) Stimulators (e.g., riociguat) is formally contraindicated due to the officially documented risk of potentiating hypotensive effects. Regulatory guidelines mandate that at least 48 hours must elapse after the last dose of Adcirca before organic nitrates may be administered.

Pharmacokinetic Interactions (Exposure Modification)

Interacting Substance Category	Official Outcome	Mechanism Focus
Potent CYP3A4 Inhibitors (e.g., Ketoconazole)	Increases tadalafil exposure (AUC and Cmax)	Reduced metabolic clearance
Potent CYP3A4 Inducers (e.g., Rifampin)	Decreases tadalafil exposure (AUC)	Increased metabolic clearance

Co-administration with alpha-blockers (e.g., doxazosin) and other antihypertensives may result in an additive hypotensive effect, potentially leading to symptomatic hypotension. Furthermore, official labeling notes an interaction with substantial alcohol consumption (ge 5 units), which may increase blood pressure-lowering effects. Specific restrictions also apply to patients with severe renal impairment, where use is advised against due to potentially increased exposure.

Inhibition of the PDE-5 Enzyme

Adcirca functions as a selective inhibitor of the Phosphodiesterase type 5 (PDE-5) enzyme, which is concentrated in the smooth muscle cells of the pulmonary arteries. This molecular action involves the drug binding to the enzyme, thereby preventing it from hydrolyzing cyclic guanosine monophosphate (cGMP).

Sustaining the NO-cGMP Signaling Pathway

The inhibition of PDE-5 leads to an elevated concentration of cGMP within the vascular smooth muscle cells. This accumulation sustains and reinforces the downstream signaling sequence initiated by Nitric Oxide (NO), which is the key mediator in this pathway. The modulation of this cascade facilitates cellular processes that reduce muscle tone.

Producing Pulmonary Vascular Relaxation

The final consequence of the elevated cGMP signal is the relaxation of the smooth muscle surrounding the pulmonary arteries (vasodilation). This physical widening of the vessels reduces the resistance to blood flow within the pulmonary circulation, and the resulting change in flow resistance contributes to a measurable decline in pressure within the pulmonary vascular system.

How to Use Adcirca: Administration Guidelines

Adcirca (tadalafil) is administered as a once-daily oral treatment for the management of Pulmonary Arterial Hypertension (PAH). The standard usage pattern is a continuous daily regimen intended for long-term therapy.

---

Standard Dosing and Frequency

The recommended standard dose for adults is 40 mg once daily. This is achieved by taking two 20 mg film-coated tablets simultaneously. This 40 mg dose is taken as a single unit; it is not divided into smaller doses throughout the day. The tablets are swallowed whole with water and may be taken with or without food.

---

Administration in Specific Populations and Scenarios

Dose adjustments are based on specific clinical scenarios, not age alone. For instance, in cases of mild to moderate renal impairment, the regimen may start at a lower dose of 20 mg once daily. Use is generally avoided in cases of severe renal impairment or severe hepatic impairment.

If a dose is missed, the dose is typically taken as soon as it is remembered within the same day. However, a double dose is not taken to compensate for the missed dose. Dose adjustments are also required when Adcirca is co-administered with certain other medications, such as ritonavir.

Research evidence / Overview of Studies for Adcirca

Evidence from Core Trials in Adults with PAH (WHO Group I)

The research base for Adcirca (tadalafil) for Pulmonary Arterial Hypertension (PAH) includes findings from short-term, randomized, double-blind trials where an active substance was compared to a placebo. These studies included adults with PAH who had symptoms classified as WHO Functional Class II or III. Researchers primarily monitored outcomes reflecting daily functioning, particularly the Six-Minute Walk Distance (6MWD) test, over a 16-week period. Findings described patterns where the group receiving the approved dose reported a walk distance that was different compared to the placebo group; for instance, a difference of 33 meters (m) was reported in the primary trial. Studies also reported data showing patterns related to the time elapsed before experiencing a clinical worsening event, with observed differences compared to the placebo group.

Research on Combination Therapy and Specific PAH Types

Adcirca was evaluated in studies alongside treatments such as Endothelin Receptor Antagonists (ERAs). These combination studies explored how outcomes related to daily functioning evolved when Adcirca was added to an existing background therapy like bosentan. Research also describes patterns observed in specific PAH subtypes, such as PAH associated with certain connective tissue diseases, which contributed to understanding symptom patterns across the broader patient population.

Studies in Pediatric Patients (Age 2+) and Long-Term Evidence

Adcirca was evaluated in a separate set of randomized, controlled research involving children aged 2 years and older with PAH. Due to the rarity of pediatric PAH, these studies involved small sample sizes, and functional assessment was adapted, including the use of hemodynamic parameters. Since PAH is a chronic condition, the duration of follow-up was studied for an extended time through open-label extension studies that provided follow-up data sometimes extending over multiple years. However, long-term effects are not fully established by the controlled data.

Evidence Quality and Areas of Remaining Uncertainty

Key areas where data remain insufficient or uncertain include definitive assessment of the relationship between Adcirca and all-cause mortality, as individual trials were generally underpowered for this outcome. Additionally, existing research has explored the use of the medicine in other forms of pulmonary hypertension, but findings were mixed or inconsistent. Study results reflect the specific conditions under which they were conducted. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain—about the medicine.

Key Studies & References

1. NIH DailyMed: Tadalafil tablet (for general drug information and clinical pharmacology)

Common questions about Adcirca (FAQ)

Q: Is Adcirca the same as the drug used for erectile dysfunction?

A: Adcirca contains the same active ingredient, tadalafil, as Cialis, a medicine approved for erectile dysfunction (ED). However, Adcirca is specifically approved by regulatory bodies to treat pulmonary hypertension at a different dose and for a distinct purpose. Official safety warnings indicate that Adcirca should not be taken together with Cialis or any other PDE5 inhibitor drug.

---

Q: What makes Adcirca different from other drugs for PAH?

A: Adcirca is used to treat Pulmonary Arterial Hypertension (PAH) in a distinctive way among its class. According to regulatory documents, the recommended dose is a single, once-daily regimen. This once-a-day formulation is a key difference from other PDE5 inhibitors used for PAH, which may require multiple daily doses.

---

Q: Is Adcirca the same as Revatio?

A: No. Adcirca and Revatio are different medicines, though both belong to the same class of drugs called PDE5 inhibitors and are approved for PAH. They contain different active ingredients and have different official doses and administration schedules.

---

Q: Are there different strengths of Adcirca tablets?

A: The official product information states that Adcirca is supplied only as a 20 mg oral tablet. The typical recommended daily dose of 40 mg is achieved by taking two of these 20 mg tablets at the same time, once a day.

---

Q: Does Adcirca interact with herbal supplements like St. John's wort?

A: Official labeling warns that the concurrent use of Adcirca with potent CYP3A4 inducers—a category that includes St. John's wort—is not recommended. These substances can decrease the concentration of tadalafil in the blood, potentially reducing the medicine's effectiveness.

---

Q: Can Adcirca interact with non-prescription pain relievers?

A: Information derived from drug interaction guidelines suggests caution with certain non-prescription pain relievers. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may lessen the blood pressure-lowering effect of tadalafil. Information about all medicines should be discussed with a healthcare provider.

---

Q: Are there specific symptoms that signal a serious reaction to Adcirca?

A: Yes. Official safety information advises seeking immediate medical attention if certain severe symptoms are experienced. These include sudden loss of vision (associated with NAION), an erection lasting longer than four hours (Priapism), or symptoms of heart trouble such as sudden chest pain or dizziness.

---

Q: Is Adcirca safe to take if I have liver problems?

A: Adcirca is not recommended for use in individuals who have severe hepatic impairment (a serious form of liver disease). Regulatory documents state that for mild or moderate hepatic impairment, a lower starting dose may be considered.

---

Q: Can women take Adcirca, or is it only for men?

A: Adcirca is approved for the treatment of PAH in adults, including both men and women. The official label includes specific warnings regarding use in women who are pregnant or breastfeeding, emphasizing that the potential benefits must outweigh the potential risks.

---

Q: Why is Adcirca prescribed for high blood pressure in the lungs and not regular high blood pressure?

A: Adcirca is officially indicated only for treating high blood pressure in the lungs, known as Pulmonary Arterial Hypertension (PAH). While the medicine promotes the widening of blood vessels, it is not approved or indicated by regulatory agencies to treat systemic, or regular, high blood pressure.

---

Q: Does Adcirca have a generic version available?

A: Yes, the active ingredient in Adcirca, tadalafil, is available as a generic version. This information is typically confirmed by governmental drug resources such as the FDA’s listing of approved drugs.

---

Q: Does Adcirca have any reported interactions with grapefruit juice?

A: Grapefruit juice can interfere with the enzyme that processes tadalafil in the body, which might increase the amount of medicine in the bloodstream. While the manufacturer may not have specifically studied this interaction, caution is generally suggested by drug-food interaction resources.

---

Q: Does Adcirca cause any changes in mood or anxiety?

A: Changes in mood or anxiety are not listed as common side effects of Adcirca based on clinical trial data. However, post-marketing reports for drugs in this class have included some mentions of psychiatric adverse events, although the official information does not establish a clear link to Adcirca.

---

Q: Is Adcirca known to affect fertility in men or women?

A: Official information derived from studies indicates that in men, tadalafil caused a slight reduction in sperm concentration in some trials. However, this change was not observed to be associated with an alteration in fertility. Animal studies showed no negative effects on fertility.

---

Q: How long does Adcirca stay in my system after I take it?

A: The official product information notes that the mean elimination half-life of tadalafil in PAH patients is approximately 35 hours. The half-life refers to the amount of time required for half of the medicine to be cleared from the bloodstream.

---

Q: Are skin rashes a possible side effect of Adcirca?

A: Yes. Official adverse event listings include rash and urticaria (hives) as uncommon side effects (occurring in less than 1 in 100 people). Serious skin reactions have also been reported rarely in post-marketing experience.

Storage and Handling Requirements

Adcirca (tadalafil) must be stored according to defined environmental constraints to maintain its stability, as specified in regulatory labeling.

Storage Component	Official Requirement
Temperature	Store at controlled room temperature between 15 C and 30 C (59 F and 86 F).
Protection	Keep in the original package to protect the tablets from moisture and humidity.
Child Safety	Must be kept out of the reach and sight of children.
Stability	Do not use the tablets after the expiry date printed on the container.

Disposal Instructions

Proper disposal is required for unused or expired medication to prevent accidental exposure and environmental contamination.

• Method: Consult a pharmacist or utilize a drug take-back program for the best disposal option. Disposal must comply with local regulations.
• Prohibition: The medication must not be disposed of in wastewater (e.g., flushed down the toilet or poured down a drain).